PREGNANCY OUTCOME AFTER TREATMENT WITH THE ERGOT DERIVATIVE, CABERGOLINE

The goal of this article is to assess the reproductive safety of caber goline, a new ergot derivative proposed in hyperprolactinemic disorder s, Investigated in different animal species, the drug showed no terato genic or embryotoxic effects on rabbits, Considering the dose envisage d for humans, large safety margins exist. Our sample consists of 226 p regnancies occurring in 205 women, Follow-up is available for 204. The re were 24 miscarriages and three abortions induced because of major m alformations (one Down syndrome in a 42-year-old woman, one limb-body wall complex, one hydrocephalus), Two of the 148 single liveborn infan ts had significant malformations: one megaureter, one scaphocephaly, T his series shows no increase in miscarriage rate, a distribution of bi rthweights and sex ratio within the expected range, and no increased r ate of congenital malformations, Follow-up of babies, limited to 107 c ases, thus far indicates normal physical and mental development.